Brasofensine Treatment for Parkinson's Disease in Combination with Levodopa/Carbidopa
Annals of Pharmacotherapy2002Vol. 36(2), pp. 225–230
Citations Over Time
Edyta J. Frackiewicz, Stanford S. Jhee, Thomas Shiovitz, Jonathan Webster, Christine Topham, Randy Dockens, Daisy B. Whigan, Daniel E. Salazar, Neal R. Cutler
Abstract
Brasofensine was safe and well tolerated in the patient cohort studied at daily doses of up to 4 mg. Adverse events were generally mild in intensity, and included headache, insomnia, phlebitis, dizziness, ecchymosis, and vomiting.
Related Papers
- → The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa(2009)36 cited
- → Controlled Release Levodopa/Carbidopa 25/100 (Sinemet CR 25/100)(1994)17 cited
- → COMPARISON OF ENTERIC‐COATED LEVODOPA WITH LEVODOPA–CARBIDOPA COMBINATION(1979)4 cited
- → Increased Dosage of Carbidopa in Parkinsonian Patients on Low Carbidopa-Levodopa Regimen(1989)2 cited
- → Liquid Chromatographic Determination of Levodopa and Levodopa-Carbidopa in SolidDosage Forms: Collaborative Study(1987)1 cited